Hexarelin Dosage: GHRP Protocol, Desensitization & Cycling Guide

Overview

Hexarelin is a synthetic growth hormone releasing peptide (GHRP) — one of the most potent GHRPs studied to date in terms of the magnitude of growth hormone (GH) release it stimulates per dose. It belongs to the same family as GHRP-2 and GHRP-6 but is distinguished by its particularly strong GH secretagogue activity and by its well-documented tendency to cause receptor desensitization with ongoing use. Understanding Hexarelin's dosing protocol, the clinical significance of desensitization, and how cycling and stacking strategies address this phenomenon is essential for interpreting the research context surrounding this peptide.

Hexarelin: Mechanism and Research Context

Hexarelin (hexarelin acetate) is a synthetic hexapeptide that acts as an agonist at the growth hormone secretagogue receptor (GHSR-1a), commonly referred to as the ghrelin receptor. By binding to GHSR-1a in the pituitary gland and hypothalamus, Hexarelin stimulates the pulsatile release of growth hormone from somatotroph cells with an efficacy that exceeds several other GHRPs studied under comparable conditions. In preclinical research, Hexarelin has also been shown to bind to CD36 receptors in cardiac tissue, independent of its GH-releasing activity, and to exert cardioprotective effects in animal models of ischemia-reperfusion injury. This dual mechanism — GH secretagogue activity plus direct cardiac receptor binding — has made Hexarelin a subject of interest beyond simple GH elevation, with research exploring its potential in cardiac protection and metabolic modulation. Growth hormone released in response to Hexarelin exerts downstream effects through the production of insulin-like growth factor 1 (IGF-1) primarily in the liver. The GH/IGF-1 axis plays central roles in protein synthesis, lean muscle preservation, fat metabolism, connective tissue repair, and immune function — mechanisms that underlie the interest in GHRP-based peptides for recovery, body composition, and anti-aging research. Because Hexarelin stimulates endogenous GH release rather than directly administering exogenous GH, its use is associated with a pulsatile release pattern that more closely mimics physiological GH secretion than exogenous GH injections. However, this also means that the extent of GH release is subject to individual variation in pituitary responsiveness and baseline GH axis function.

Research Doses: 100–200 mcg Per Injection

Hexarelin research protocols consistently describe doses in the range of 100–200 mcg per injection. This range represents the doses examined in published human and animal studies showing meaningful GH release, and it aligns with the dosing conventions used by practitioners administering Hexarelin in clinical research settings. At the lower end of this range, 100 mcg doses have been used in published human studies examining Hexarelin's GH secretagogue activity. These doses produced significant, measurable GH pulses in healthy subjects, demonstrating that even the lower portion of the research dose range is biologically active in humans. Doses of 200 mcg represent the higher end of commonly discussed research doses and have been associated with greater peak GH release in dose-response observations. Some protocols describe doses up to 300 mcg, though diminishing returns become more apparent at higher doses as pituitary responsiveness is partly saturated and the contribution of additional peptide to incremental GH release declines. The commonly recommended research starting point is 100 mcg per injection, with potential upward adjustment to 150–200 mcg based on individual response. Hexarelin is considerably more potent on a per-microgram basis than GHRP-6, meaning that the same dose of Hexarelin generally produces greater GH release than an equivalent dose of GHRP-6. This higher potency also means that the desensitization concern (discussed in a subsequent section) is more pronounced with Hexarelin than with less potent GHRPs. Body weight is sometimes used as a dosing reference in research contexts — doses of approximately 1–2 mcg per kilogram of body weight have been used in studies — which would translate to approximately 80–160 mcg for a typical 80 kg adult, broadly consistent with the 100–200 mcg range commonly cited.

• Standard research dose range: 100–200 mcg per injection
• Lower-range dose (100 mcg): active in published human GH studies
• Upper-range dose (200 mcg): higher peak GH release; greater desensitization risk
• Weight-based approximation: 1–2 mcg/kg body weight

Dosing Frequency: 2–3 Times Daily

Hexarelin protocols in research contexts typically involve 2–3 injections per day, spaced to align with the pulsatile nature of endogenous GH secretion and to maximize total daily GH output. The rationale for multiple daily doses rather than a single daily injection reflects the short duration of GH elevation following each Hexarelin administration — peak GH levels are typically observed within 15–30 minutes of injection and return toward baseline within 1–2 hours. By spacing injections throughout the day, protocols attempt to create multiple GH pulses that collectively provide a greater total exposure to elevated GH and IGF-1 than would be achievable with a single injection. A common three-times-daily protocol involves administering Hexarelin upon waking (in a fasted state), approximately 30 minutes before the day's primary workout or physical activity, and shortly before bedtime. The morning fasted injection takes advantage of the naturally heightened pituitary responsiveness to GH secretagogues in the fasted state, when somatostatin tone — the inhibitory signal that counteracts GH release — is relatively low. The pre-workout injection is timed to amplify the exercise-induced GH pulse that accompanies intense resistance training, potentially creating a synergistic effect between peptide stimulation and exercise-driven GH release. The pre-sleep injection targets the large physiological GH pulse that typically occurs during slow-wave sleep, the period of maximal endogenous GH secretion. By priming pituitary responsiveness before sleep onset, the pre-sleep injection is intended to augment this natural nocturnal GH pulse. Practitioners who prefer a two-times-daily protocol typically retain the morning fasted and pre-sleep injections, removing the pre-workout dose. This approach reduces the total injection burden while preserving the two timing windows considered most important for GH axis optimization. The specific spacing between injections should allow sufficient time for GH levels to return toward baseline before the next stimulation — generally a minimum of 3 hours between doses is recommended to avoid blunting the subsequent GH response due to residual somatostatin elevation.

Pre-Workout Timing and Exercise Synergy

The pre-workout administration timing of Hexarelin merits specific discussion because the interaction between GHRP stimulation and exercise-induced GH release is a core element of many research protocols. Intense resistance exercise is itself a potent stimulus for GH secretion through several mechanisms, including metabolic acidosis, lactate accumulation, and direct pituitary activation. The magnitude of the exercise-induced GH pulse correlates with exercise intensity and volume, making high-intensity resistance training sessions particularly relevant for protocols aiming to maximize GH output. Administering Hexarelin 20–30 minutes before the start of intense exercise positions the peak GHRP-stimulated GH pulse to coincide with the exercise-induced GH response. Whether this co-occurrence produces a truly additive or synergistic combined GH peak, or whether the two stimuli simply operate through partially overlapping mechanisms, has not been definitively established in controlled research for Hexarelin specifically. However, the general principle that GH secretagogues and exercise act through mechanisms that can produce larger combined GH pulses than either alone is supported by research on the GHRP class more broadly. Some protocols recommend allowing at least 90–120 minutes of fasting before the pre-workout injection as well, since elevated blood glucose and insulin levels following a meal reduce pituitary sensitivity to GHRP stimulation — the same mechanism that underlies the general recommendation to administer GHRPs in a fasted state. Individuals who train in the evening and use a three-times-daily protocol may consolidate the pre-workout and pre-sleep doses, recognizing that injecting Hexarelin late in the evening before sleep encompasses both objectives.

Desensitization: The Critical Cycling Requirement

Desensitization — the progressive reduction in GH release produced by a given dose of Hexarelin with continued use — is the defining pharmacological challenge of Hexarelin protocols and the primary reason that cycling is not merely recommended but considered essential. Unlike some other peptides where cycling is primarily a precautionary convention, with Hexarelin the loss of efficacy with continuous use is a documented phenomenon observed in research. The mechanism of Hexarelin desensitization involves multiple components. At the receptor level, sustained GHSR-1a activation leads to receptor downregulation — a reduction in the total number of functional ghrelin receptors expressed on pituitary somatotroph cells — and receptor desensitization, where the remaining receptors become less responsive to ligand binding. At the signaling level, continuous stimulation of the GH secretory pathway leads to compensatory upregulation of somatostatin — the inhibitory neuropeptide that counteracts GH release — and downregulation of GHRH receptor sensitivity, both of which further reduce the GH response to Hexarelin over time. Research has demonstrated that Hexarelin produces greater and faster desensitization than less potent GHRPs such as GHRP-6 or GHRP-2, which is consistent with the general pharmacological principle that more potent receptor agonists tend to produce more pronounced desensitization with sustained use. Functionally, this means that individuals using Hexarelin continuously will observe a gradual decline in the GH-releasing response over weeks, with continued use beyond the desensitization threshold producing little additional benefit while maintaining the injection burden and associated costs. A cycling strategy is specifically designed to allow receptor recovery during the off period. The standard approach involves using Hexarelin for 4–6 weeks, then abstaining for at least 4 weeks to allow receptor number, sensitivity, and somatostatin tone to normalize before the next cycle. This rest period is not merely conventional — without adequate recovery time, the diminished responsiveness of the GH axis may persist into the next cycle, reducing its effectiveness.

• Desensitization mechanism: GHSR-1a downregulation, receptor desensitization, elevated somatostatin
• Hexarelin causes more pronounced desensitization than less potent GHRPs
• Standard cycle: 4–6 weeks on, minimum 4 weeks off
• Ignoring cycling leads to progressively diminished GH response

Stacking with GHRH: CJC-1295 and Sermorelin

Hexarelin is frequently used in research protocols in combination with a growth hormone releasing hormone (GHRH) analogue such as CJC-1295 (with or without DAC) or Sermorelin. This stacking strategy is based on a well-established principle in GH axis pharmacology: GHRPs and GHRHs act through distinct, synergistic mechanisms at the pituitary level, and their co-administration produces GH pulses substantially larger than those achieved with either agent alone. GHRH (and its analogues) acts at the GHRH receptor on pituitary somatotrophs, stimulating GH gene transcription and directly promoting GH synthesis and secretion. Hexarelin acts at the GHSR-1a, which uses a different intracellular signaling pathway to promote GH release and also works by reducing the inhibitory influence of somatostatin. When both pathways are activated simultaneously, the combined effect on GH secretion is synergistic rather than merely additive — the magnitude of GH release with the combination substantially exceeds the sum of the individual responses. Research has quantified this synergy in human studies using other GHRP/GHRH combinations, showing GH peaks several times larger with combined administration compared to either peptide alone. A typical stacking protocol involves co-administering Hexarelin (100–200 mcg) with CJC-1295 without DAC (also known as Modified GRF 1-29, at 100–200 mcg) as a single injection, with the two peptides often reconstituted separately and drawn into the same syringe immediately before administration. The same timing principles that apply to Hexarelin alone — fasted state, pre-workout, pre-sleep — apply to the combination protocol. The desensitization concern remains relevant for the stacked protocol, and cycling schedules should be maintained as they would for Hexarelin alone. Some practitioners prefer Sermorelin as the GHRH component for its shorter half-life and the more physiological pulsatile GH response it produces compared to CJC-1295 with DAC.

Reconstitution and SubQ Injection Technique

Hexarelin is supplied as a lyophilized powder and is reconstituted with bacteriostatic water before injection, following the same general principles applicable to other research peptides. For a standard 2 mg vial, reconstituting with 2 mL of bacteriostatic water yields a concentration of 1 mg/mL (1000 mcg/mL), allowing each 0.1 mL drawn in an insulin syringe to deliver 100 mcg. This concentration provides convenient dosing for research protocols using 100–200 mcg doses without requiring the injection of very small or very large volumes. Bacteriostatic water should be added to the vial slowly and gently, directed down the inner wall of the vial rather than directly onto the powder cake. The vial should be swirled gently to dissolve the peptide rather than shaken, as mechanical agitation can cause peptide aggregation and degradation. Reconstituted Hexarelin should be stored refrigerated at 2–8°C and is generally considered stable for 2–4 weeks under these conditions. The lyophilized powder is more stable and should be stored in a cool, dark environment, or at −20°C for longer-term storage. Subcutaneous injection is the standard route for Hexarelin administration in research contexts. The most common injection sites are the abdomen (approximately 2 inches from the navel), upper thigh, and upper outer arm — areas where a pinched fold of skin and subcutaneous fat can be easily accessed with a short insulin syringe needle (28–31 gauge, 5/16"–1/2" needle length). Standard aseptic technique applies: clean the injection site with an alcohol wipe, allow it to dry completely, inject at approximately 45–90 degrees depending on body composition and needle length, inject slowly and steadily, and withdraw the needle smoothly before releasing the skin fold. Rotating injection sites with each administration helps prevent local tissue irritation from repeated injection at the same location.

References

1. Hexarelin, a synthetic GH-releasing peptide, activates the hypothalamic-pituitary axis in rats (1994) — PubMed
2. Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, after intravenous, subcutaneous, intranasal, and oral administration (1995) — PubMed
3. Hexarelin treatment in adult patients with GH deficiency (2000) — PubMed
4. Desensitization to growth hormone-releasing peptides in normal male volunteers (1997) — PubMed
5. Hexarelin and cardioprotection: receptor binding at CD36 (2004) — PubMed